Sign in3 stories
Moderna named Juan Andres Chief Operating Officer effective October 5, 2026, as the company said it prepares for a possible launch of its cancer therapy intismeran autogene and expands its vaccine lineup.
SEC filing
The private placement closed September 1, 2026, after initial purchasers fully exercised their option for additional notes, with proceeds earmarked partly for oncology and debt repayment.
SEC filing
The company said mRNA-1403 did not clear a Phase 3 interim efficacy threshold as it awaits an August 5 FDA decision on flu vaccine mFLUSIVA.
SEC filing